Narges Alizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Narges Alizadeh has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Darjani
Department of Dermatology, Skin Research Center, Guilan University of Medical Sciences, Rasht, Iran
6 shared publications - Hojat Eftekhari
Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
5 shared publications - Kaveh Gharaei Nejad
Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
5 shared publications - Rana Rafiei
Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
4 shared publications - Elahe Rafiei
Razi Clinical Research Development Unit, Guilan University of Medical Sciences, Rasht, Iran
3 shared publications - Abbas Darjani
Skin Research Center, Department of Dermatology, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
2 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 483
Demodex infestation in benign and malignant skin tumors
- 23 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 483
Demodex infestation in benign and malignant skin tumors
- 19 December 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-5
Is vitamin D deficiency a more frequent finding in hirsutism or not?
Evidence shows that vitamin D (Vit D) insufficiency is associated with some hormonal disorders. Hirsutism is a prevalent hormonal condition, which is usually associated with excess of androgenic hormones. Disturbance of Vit D level affects the regulation of these hormones and may be associated with hirsutism. This study compared the Vit D levels of women with and without hirsutism. The study aimed to answer the question “Do women with hirsutism more commonly have lower levels of vitamin D compared to women without hirsutism”. In this cross-sectional study, 202 women were included (101 with hirsutism and 101 without hirsutism). 25-hydroxy Vit D level was assessed using high-performance liquid chromatography (HPLC). All data was analyzed based on a significance level < 0.05. The age distribution was similar in both groups (P > 0.05). The mean level of Vit D had no statistically significant differences between the hirsutism group (21.40 ng/ml) and non-hirsutism group (21.20 ng/ml) (P > 0.05). Also, no significant correlations between menstrual patterns, body mass index and presence of polycystic ovaries, with different levels of Vit D were observed in hirsute women (P > 0.05). The study found no significant difference in Vit D levels between individuals with and without hirsutism. About half of the individuals in both groups had Vit D deficiency. But these findings do not rule out the possible role of vitamin D deficiency in the development of hirsutism.
- 19 December 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-5
Is vitamin D deficiency a more frequent finding in hirsutism or not?
Evidence shows that vitamin D (Vit D) insufficiency is associated with some hormonal disorders. Hirsutism is a prevalent hormonal condition, which is usually associated with excess of androgenic hormones. Disturbance of Vit D level affects the regulation of these hormones and may be associated with hirsutism. This study compared the Vit D levels of women with and without hirsutism. The study aimed to answer the question “Do women with hirsutism more commonly have lower levels of vitamin D compared to women without hirsutism”. In this cross-sectional study, 202 women were included (101 with hirsutism and 101 without hirsutism). 25-hydroxy Vit D level was assessed using high-performance liquid chromatography (HPLC). All data was analyzed based on a significance level < 0.05. The age distribution was similar in both groups (P > 0.05). The mean level of Vit D had no statistically significant differences between the hirsutism group (21.40 ng/ml) and non-hirsutism group (21.20 ng/ml) (P > 0.05). Also, no significant correlations between menstrual patterns, body mass index and presence of polycystic ovaries, with different levels of Vit D were observed in hirsute women (P > 0.05). The study found no significant difference in Vit D levels between individuals with and without hirsutism. About half of the individuals in both groups had Vit D deficiency. But these findings do not rule out the possible role of vitamin D deficiency in the development of hirsutism.
- 12 April 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 192 (6) , 2823-2827
Testosterone or dihydrotestosterone: what should be evaluated in hirsutism?
Purpose Dihydrotestosterone is a more potent androgen derived from testosterone and androstenediones, but its measurement has not been routinely recommended in women with hirsutism, and there is limited information in this regard with equivocal findings. This study aimed to evaluate serum dihydrotestosterone level in patients with hirsutism compared to women without hirsutism. Methods In this case–control study (during 2021–2022), serum levels of total testosterone, free testosterone, and dihydrotestosterone were evaluated in 101 women with hirsutism and 101 healthy women. Hormonal levels were measured with chemiluminescent immunoassay method. Age and hormonal levels in each group, body mass index, menstrual status, complaint of decreased scalp hair density, and ovarian ultrasound findings in hirsutism group were collected and analyzed. Results There was significant difference in free testosterone and dihydrotestosterone levels (P < 0.001) and no significant difference in total testosterone level between two groups (P = 0.628). Dihydrotestosterone level was significantly higher in women with hirsutism with menses irregularity, complaint of decreased scalp hair density, and presence of polycystic ovary on ultrasound (P < 0.05). Conclusions Measuring dihydrotestosterone level is not considered in routine evaluation of hirsutism, but we think that this significant difference shows that elevated level of dihydrotestosterone hormone in women with hirsutism is an important factor.
- 12 April 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 192 (6) , 2823-2827
Testosterone or dihydrotestosterone: what should be evaluated in hirsutism?
Purpose Dihydrotestosterone is a more potent androgen derived from testosterone and androstenediones, but its measurement has not been routinely recommended in women with hirsutism, and there is limited information in this regard with equivocal findings. This study aimed to evaluate serum dihydrotestosterone level in patients with hirsutism compared to women without hirsutism. Methods In this case–control study (during 2021–2022), serum levels of total testosterone, free testosterone, and dihydrotestosterone were evaluated in 101 women with hirsutism and 101 healthy women. Hormonal levels were measured with chemiluminescent immunoassay method. Age and hormonal levels in each group, body mass index, menstrual status, complaint of decreased scalp hair density, and ovarian ultrasound findings in hirsutism group were collected and analyzed. Results There was significant difference in free testosterone and dihydrotestosterone levels (P < 0.001) and no significant difference in total testosterone level between two groups (P = 0.628). Dihydrotestosterone level was significantly higher in women with hirsutism with menses irregularity, complaint of decreased scalp hair density, and presence of polycystic ovary on ultrasound (P < 0.05). Conclusions Measuring dihydrotestosterone level is not considered in routine evaluation of hirsutism, but we think that this significant difference shows that elevated level of dihydrotestosterone hormone in women with hirsutism is an important factor.
- Open Access
- 22 November 2022
- Published by Brieflands in Nephro-Urology Monthly
- Vol. 14 (4)
Association Between Uremic Pruritus and Serum Level of Fibroblast Growth Factor 23 in Hemodialysis Patients in North of Iran: An Observational Study
Background: Chronic itch (CI) in hemodialysis (HD), also called uremic pruritus (UP), is a common, distressing, and unpleasant symptom. Fibroblast growth factor 23 (FGF23) is a bone-secreted phosphaturic factor. Several bone diseases can accompany kidney diseases. It is unclear whether the common disturbance of calcium/phosphate homeostasis can cause CI in chronic kidney disease. Objectives: This study investigated the association between FGF23 and UP among HD patients in northern Iran. Methods: Patients undergoing maintenance HD at four referral medical centers were recruited in this cross-sectional survey. The enzyme-linked immunosorbent assay was used to evaluate serum FGF23 levels. An interview questionnaire was used to analyze the various aspects of pruritus. Results: Of 237 subjects, 54.01% had UP. There was no difference in serum FGF23 levels between patients with and without UP (413.17 ± 416.97 vs. 410.81 ± 444.49, P = 0.85). Those with UP required dialysis for a longer period (P = 0.02). FGF23 was shown to be associated with parathyroid hormone in UP (P = 0.02, r = 0.41). Conclusions: There was no linear correlation between FGF23 and UP in this study.
- 22 November 2022
- Published by Brieflands in Nephro-Urology Monthly
- Vol. 14 (4)
Open AccessAssociation Between Uremic Pruritus and Serum Level of Fibroblast Growth Factor 23 in Hemodialysis Patients in North of Iran: An Observational Study
Background: Chronic itch (CI) in hemodialysis (HD), also called uremic pruritus (UP), is a common, distressing, and unpleasant symptom. Fibroblast growth factor 23 (FGF23) is a bone-secreted phosphaturic factor. Several bone diseases can accompany kidney diseases. It is unclear whether the common disturbance of calcium/phosphate homeostasis can cause CI in chronic kidney disease. Objectives: This study investigated the association between FGF23 and UP among HD patients in northern Iran. Methods: Patients undergoing maintenance HD at four referral medical centers were recruited in this cross-sectional survey. The enzyme-linked immunosorbent assay was used to evaluate serum FGF23 levels. An interview questionnaire was used to analyze the various aspects of pruritus. Results: Of 237 subjects, 54.01% had UP. There was no difference in serum FGF23 levels between patients with and without UP (413.17 ± 416.97 vs. 410.81 ± 444.49, P = 0.85). Those with UP required dialysis for a longer period (P = 0.02). FGF23 was shown to be associated with parathyroid hormone in UP (P = 0.02, r = 0.41). Conclusions: There was no linear correlation between FGF23 and UP in this study.
- Open Access
- 28 September 2021
- Published by Brieflands in Journal of Skin and Stem Cell
- Vol. 8 (2)
The Frequency and Causes of Subepidermal Gaps or Blisters and the Compliance Rate Between Clinical Diagnosis and Pathology Reports from 2015 to 2019
Background: Skin diseases are the fourth most common cause of human illness, and blisters with different clinical manifestations make a diagnostic challenge. Objectives: This study aimed to evaluate the frequency and causes of subepidermal gaps or blisters, as well as the compliance rate between the initial and final clinical diagnoses based on pathology reports. Methods: In this cross-sectional study, pathology reports of subepidermal blisters or gaps were evaluated in the patients referred to the Razi Laboratory of Rasht from 2015 to 2019. The samples were examined by a pathologist after hematoxylin and eosin staining. The reports included demographic information, clinical differential diagnoses, final diagnosis, direct immunofluorescence findings, and salt split results. Finally, the compliance rate of clinical diagnosis with pathology reports was determined. Results: A total of 183 pathology reports were evaluated, 170 of which contained the final diagnosis. Females were more frequently affected by the disease, and pemphigoid bolus and lichen planus were the most prevalent final diagnoses. The compliance rate between the initial and final diagnoses was 94%. About 37.2% of the reports lacked direct immunofluorescence (DIF) and salt split, and only 42.6% of the samples had undergone DIF examination, while 20.2% had both DIF and salt split. There was no significant association between the compliance rate of the final diagnosis with age, sex, and undergoing diagnostic tests. Conclusions: A high incidence of subepidermal gaps or blisters was seen in middle-aged individuals and females. The compliance rate of the initial clinical diagnosis with the final diagnosis based on pathological reports was high. Our findings emphasize the importance of histopathological examination and the complementary role of direct immunofluorescence and salt split in diagnosis.
- 28 September 2021
- Published by Brieflands in Journal of Skin and Stem Cell
- Vol. 8 (2)
Open AccessThe Frequency and Causes of Subepidermal Gaps or Blisters and the Compliance Rate Between Clinical Diagnosis and Pathology Reports from 2015 to 2019
Background: Skin diseases are the fourth most common cause of human illness, and blisters with different clinical manifestations make a diagnostic challenge. Objectives: This study aimed to evaluate the frequency and causes of subepidermal gaps or blisters, as well as the compliance rate between the initial and final clinical diagnoses based on pathology reports. Methods: In this cross-sectional study, pathology reports of subepidermal blisters or gaps were evaluated in the patients referred to the Razi Laboratory of Rasht from 2015 to 2019. The samples were examined by a pathologist after hematoxylin and eosin staining. The reports included demographic information, clinical differential diagnoses, final diagnosis, direct immunofluorescence findings, and salt split results. Finally, the compliance rate of clinical diagnosis with pathology reports was determined. Results: A total of 183 pathology reports were evaluated, 170 of which contained the final diagnosis. Females were more frequently affected by the disease, and pemphigoid bolus and lichen planus were the most prevalent final diagnoses. The compliance rate between the initial and final diagnoses was 94%. About 37.2% of the reports lacked direct immunofluorescence (DIF) and salt split, and only 42.6% of the samples had undergone DIF examination, while 20.2% had both DIF and salt split. There was no significant association between the compliance rate of the final diagnosis with age, sex, and undergoing diagnostic tests. Conclusions: A high incidence of subepidermal gaps or blisters was seen in middle-aged individuals and females. The compliance rate of the initial clinical diagnosis with the final diagnosis based on pathological reports was high. Our findings emphasize the importance of histopathological examination and the complementary role of direct immunofluorescence and salt split in diagnosis.
- Open Access
- 10 August 2021
- Published by Brieflands in Journal of Skin and Stem Cell
- Vol. 8 (1)
General Health Status of Patients with Pemphigus Vulgaris
Background: Pemphigus vulgaris is a severe autoimmune disease that involves skin and mucosal membranes by blistering lesions of varying sizes. Pemphigus is often associated with psychological stress. Objectives: This study aimed to show the status of general health in patients suffering from this disease. Methods: A descriptive study was conducted on 35 new cases of pemphigus vulgaris that were referred to the tertiary level hospital from March 2017 to March 2018. Personal and clinical data were gathered by interviewing. Assessment of severity of the disease was done by the Ikeda index, and GHQ-28 questionnaires were used to measure their general health status. Results: A total of 35 new cases of non-treated pemphigus vulgaris (16 females and 19 males; mean age of 48.3 years, range 25 - 84 years) participated in this study. Median severity score of pemphigus was 4.1. Moreover, GHQ-28 positivity was detected in 65.7%o the patients. Social dysfunction and anxiety/insomnia had higher scores in subscales. There was a reverse relationship between disease severity and GHQ-28 values (P < 0.05). Conclusions: Pemphigus may negatively affect the general health of patients, and this issue should be considered in the treatment of this disease.
- 10 August 2021
- Published by Brieflands in Journal of Skin and Stem Cell
- Vol. 8 (1)
Open AccessGeneral Health Status of Patients with Pemphigus Vulgaris
Background: Pemphigus vulgaris is a severe autoimmune disease that involves skin and mucosal membranes by blistering lesions of varying sizes. Pemphigus is often associated with psychological stress. Objectives: This study aimed to show the status of general health in patients suffering from this disease. Methods: A descriptive study was conducted on 35 new cases of pemphigus vulgaris that were referred to the tertiary level hospital from March 2017 to March 2018. Personal and clinical data were gathered by interviewing. Assessment of severity of the disease was done by the Ikeda index, and GHQ-28 questionnaires were used to measure their general health status. Results: A total of 35 new cases of non-treated pemphigus vulgaris (16 females and 19 males; mean age of 48.3 years, range 25 - 84 years) participated in this study. Median severity score of pemphigus was 4.1. Moreover, GHQ-28 positivity was detected in 65.7%o the patients. Social dysfunction and anxiety/insomnia had higher scores in subscales. There was a reverse relationship between disease severity and GHQ-28 values (P < 0.05). Conclusions: Pemphigus may negatively affect the general health of patients, and this issue should be considered in the treatment of this disease.
- 13 May 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 59 (7) , 822-828
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature
Background Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy. Methods This longitudinal prospective observational study included data on women with non‐metastatic breast cancer whom were treated with AC‐T protocol (anthracycline, cyclophosphamide, and taxane) adjuvant chemotherapy and consecutively enrolled during two years. The study was performed in an educational and tertiary referral center. The patients’ information including age, body mass index (BMI), past medical history, and different dermatologic complications were collected for all participants. Results Of 190 enrolled women, all patients experienced alopecia, which occurred in 131 patients (68.9%) after the first cycle. Skin, mucosal, and nail involvement were respectively seen in 46 (24.2%), 51 (26.8%), and 86 (45.2%) cases. Cutaneous complications were observed mainly between the third and sixth chemotherapy cycles. Palmoplantar erythema and palmoplantar dysesthesia were the most common cutaneous complications. Dermatologic adverse effects were significantly more frequent in the patients with an underlying disease. Conclusion These findings suggest that dermatologic adverse effects of adjuvant chemotherapy are common and could be induced by all components of AC‐T regimen. These complications should be skillfully managed to increase patients’ comfort.
- 13 May 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 59 (7) , 822-828
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature
Background Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy. Methods This longitudinal prospective observational study included data on women with non‐metastatic breast cancer whom were treated with AC‐T protocol (anthracycline, cyclophosphamide, and taxane) adjuvant chemotherapy and consecutively enrolled during two years. The study was performed in an educational and tertiary referral center. The patients’ information including age, body mass index (BMI), past medical history, and different dermatologic complications were collected for all participants. Results Of 190 enrolled women, all patients experienced alopecia, which occurred in 131 patients (68.9%) after the first cycle. Skin, mucosal, and nail involvement were respectively seen in 46 (24.2%), 51 (26.8%), and 86 (45.2%) cases. Cutaneous complications were observed mainly between the third and sixth chemotherapy cycles. Palmoplantar erythema and palmoplantar dysesthesia were the most common cutaneous complications. Dermatologic adverse effects were significantly more frequent in the patients with an underlying disease. Conclusion These findings suggest that dermatologic adverse effects of adjuvant chemotherapy are common and could be induced by all components of AC‐T regimen. These complications should be skillfully managed to increase patients’ comfort.
- 1 July 2019
- Published by Negah Scientific Publisher in Caspian Journal of Neurological Sciences
- Vol. 5 (3) , 127-132
Anticonvulsant Drugs and Severe Adverse Cutaneous Drug Reactions: A Longitudinal Observational Study
Background: Severe Adverse Cutaneous Reactions to Drugs (SACRDs) are skin eruptions due to drugs, which can cause morbidity and morbidity in patients. Objectives: The aim of this study was to determine the offending drug/agents and clinical phenotypes of SACRDs leading to admissions to the hospital. Materials & Methods: We conducted a retrospective cross-sectional study during one year (March 2012-2013) on patients admitted to the department of Dermatology at Razi Hospital of Rasht, Iran. First, the clinical and drug history of all patients were collected. Then, two dermatologists examined them and diagnosed drug eruptions according to the clinical types of adverse drug reactions included in the study. Collected data were analyzed in SPSS V. 18 software by using Chi-squared test, Fisherchr('39')s Exact test, and one-way ANOVA. The significance level was set at p<0.05. Results: Forty-six patients were diagnosed with SACRDs. The most common SACRDs were toxic epidermal necrolysis/stevens Johnson syndrome (TEM/SJS) and Drug Reaction with eosinophilia and systemic symptom syndrome (DRESS) syndrome (30.5% and 2.1%, respectively). The most common culprit drugs were anticonvulsants (43.5%) and antibiotics (26.1%). Peripheral blood eosinophilia was observed in 30.4% of patients. Conclusion: Anticonvulsants were the most common cause of ACDRs, leading to the hospitalization of the patients.
- 1 July 2019
- Published by Negah Scientific Publisher in Caspian Journal of Neurological Sciences
- Vol. 5 (3) , 127-132
Anticonvulsant Drugs and Severe Adverse Cutaneous Drug Reactions: A Longitudinal Observational Study
Background: Severe Adverse Cutaneous Reactions to Drugs (SACRDs) are skin eruptions due to drugs, which can cause morbidity and morbidity in patients. Objectives: The aim of this study was to determine the offending drug/agents and clinical phenotypes of SACRDs leading to admissions to the hospital. Materials & Methods: We conducted a retrospective cross-sectional study during one year (March 2012-2013) on patients admitted to the department of Dermatology at Razi Hospital of Rasht, Iran. First, the clinical and drug history of all patients were collected. Then, two dermatologists examined them and diagnosed drug eruptions according to the clinical types of adverse drug reactions included in the study. Collected data were analyzed in SPSS V. 18 software by using Chi-squared test, Fisherchr('39')s Exact test, and one-way ANOVA. The significance level was set at p<0.05. Results: Forty-six patients were diagnosed with SACRDs. The most common SACRDs were toxic epidermal necrolysis/stevens Johnson syndrome (TEM/SJS) and Drug Reaction with eosinophilia and systemic symptom syndrome (DRESS) syndrome (30.5% and 2.1%, respectively). The most common culprit drugs were anticonvulsants (43.5%) and antibiotics (26.1%). Peripheral blood eosinophilia was observed in 30.4% of patients. Conclusion: Anticonvulsants were the most common cause of ACDRs, leading to the hospitalization of the patients.
- Open Access
- 1 October 2017
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 9, 777-780
Can laser treatment improve quality of life of hirsute women?
Background: Hirsutism can have negative impacts on psychosocial aspects of women’s lives and reduce their quality of life (QOL). The aim of this study was to assess the QOL of these women during laser treatment. Patients and methods: Eighty-eight women with unwanted facial hair underwent laser therapy. Each patient completed a questionnaire consisting of a modified Dermatology Life Quality Index (DLQI) and visual analog scale (VAS) before the first, third, and fifth sessions of laser therapy. Interval between the sessions was 4–6 weeks. Statistical analyses were done using SPSS software version18. Results: The DLQI scores before treatment, and at third and fifth sessions were 7.75±2.36, 5.55±1.88, and 4.14±0.64, respectively (PP Conclusion: Hair removal with laser therapy can improve the QOL in hirsute women. Also, socioeconomic status does not affect the satisfaction rate of laser therapy for hair removal.
- 1 October 2017
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 9, 777-780
Open AccessCan laser treatment improve quality of life of hirsute women?
Background: Hirsutism can have negative impacts on psychosocial aspects of women’s lives and reduce their quality of life (QOL). The aim of this study was to assess the QOL of these women during laser treatment. Patients and methods: Eighty-eight women with unwanted facial hair underwent laser therapy. Each patient completed a questionnaire consisting of a modified Dermatology Life Quality Index (DLQI) and visual analog scale (VAS) before the first, third, and fifth sessions of laser therapy. Interval between the sessions was 4–6 weeks. Statistical analyses were done using SPSS software version18. Results: The DLQI scores before treatment, and at third and fifth sessions were 7.75±2.36, 5.55±1.88, and 4.14±0.64, respectively (PP Conclusion: Hair removal with laser therapy can improve the QOL in hirsute women. Also, socioeconomic status does not affect the satisfaction rate of laser therapy for hair removal.
- Open Access
- 18 February 2014
- Published by Hindawi Limited in Dermatology Research and Practice
- Vol. 2014, 1-5
Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis
Background. Topical agents can be unpleasant due to long-term therapies in patients with moderate to severe seborrheic dermatitis. Systemic antifungal therapy is another alternative in treatment.Aim. This study was conducted to compare the efficacy of oral fluconazole and terbinafine in the treatment of moderate to severe seborrheic dermatitis.Methods. 64 patients with moderate to severe seborrheic dermatitis (SD) were enrolled in a randomized, parallel-group study. One study group took terbinafine 250 mg daily () and the other one fluconazole 300 mg () weekly for four weeks. Seborrheic dermatitis area severity index (SDASI) and the intensity of itching were calculated before, at the end of treatment, and two weeks after treatment.Results. Both drugs significantly reduced the severity of seborrheic dermatitis (). Multivariate linear regression revealed that efficacy of terbinafine is more than fluconazole (, 95% CI (0.63–4.7)). Moreover, each index of SD severity reduced 0.9 times after treatment. (, 95% CI (0.8–1.02)). The itching rate significantly diminished (); however, there was no difference between these two drugs statistically.Conclusions. Both systemic antifungal therapies may reduce the severity index of SD. However, terbinafine showed more reduction in the intensity of the disease. In other words, the more the primary intensity of the disease is, the more its reduction will be. This trial is resgistered with201102205871N1.- 18 February 2014
- Published by Hindawi Limited in Dermatology Research and Practice
- Vol. 2014, 1-5
Open AccessComparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis
Background. Topical agents can be unpleasant due to long-term therapies in patients with moderate to severe seborrheic dermatitis. Systemic antifungal therapy is another alternative in treatment.Aim. This study was conducted to compare the efficacy of oral fluconazole and terbinafine in the treatment of moderate to severe seborrheic dermatitis.Methods. 64 patients with moderate to severe seborrheic dermatitis (SD) were enrolled in a randomized, parallel-group study. One study group took terbinafine 250 mg daily () and the other one fluconazole 300 mg () weekly for four weeks. Seborrheic dermatitis area severity index (SDASI) and the intensity of itching were calculated before, at the end of treatment, and two weeks after treatment.Results. Both drugs significantly reduced the severity of seborrheic dermatitis (). Multivariate linear regression revealed that efficacy of terbinafine is more than fluconazole (, 95% CI (0.63–4.7)). Moreover, each index of SD severity reduced 0.9 times after treatment. (, 95% CI (0.8–1.02)). The itching rate significantly diminished (); however, there was no difference between these two drugs statistically.Conclusions. Both systemic antifungal therapies may reduce the severity index of SD. However, terbinafine showed more reduction in the intensity of the disease. In other words, the more the primary intensity of the disease is, the more its reduction will be. This trial is resgistered with201102205871N1.